TY - JOUR
T1 - Altered ubiquitin signaling induces Alzheimer’s disease-like hallmarks in a three-dimensional human neural cell culture model
AU - Maniv, Inbal
AU - Sarji, Mahasen
AU - Bdarneh, Anwar
AU - Feldman, Alona
AU - Ankawa, Roi
AU - Koren, Elle
AU - Magid-Gold, Inbar
AU - Reis, Noa
AU - Soteriou, Despina
AU - Salomon-Zimri, Shiran
AU - Lavy, Tali
AU - Kesselman, Ellina
AU - Koifman, Naama
AU - Kurz, Thimo
AU - Kleifeld, Oded
AU - Michaelson, Daniel
AU - van Leeuwen, Fred W.
AU - Verheijen, Bert M.
AU - Fuchs, Yaron
AU - Glickman, Michael H.
N1 - Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/12
Y1 - 2023/12
N2 - Alzheimer’s disease (AD) is characterized by toxic protein accumulation in the brain. Ubiquitination is essential for protein clearance in cells, making altered ubiquitin signaling crucial in AD development. A defective variant, ubiquitin B + 1 (UBB+1), created by a non-hereditary RNA frameshift mutation, is found in all AD patient brains post-mortem. We now detect UBB+1 in human brains during early AD stages. Our study employs a 3D neural culture platform derived from human neural progenitors, demonstrating that UBB+1 alone induces extracellular amyloid-β (Aβ) deposits and insoluble hyperphosphorylated tau aggregates. UBB+1 competes with ubiquitin for binding to the deubiquitinating enzyme UCHL1, leading to elevated levels of amyloid precursor protein (APP), secreted Aβ peptides, and Aβ build-up. Crucially, silencing UBB+1 expression impedes the emergence of AD hallmarks in this model system. Our findings highlight the significance of ubiquitin signalling as a variable contributing to AD pathology and present a nonclinical platform for testing potential therapeutics.
AB - Alzheimer’s disease (AD) is characterized by toxic protein accumulation in the brain. Ubiquitination is essential for protein clearance in cells, making altered ubiquitin signaling crucial in AD development. A defective variant, ubiquitin B + 1 (UBB+1), created by a non-hereditary RNA frameshift mutation, is found in all AD patient brains post-mortem. We now detect UBB+1 in human brains during early AD stages. Our study employs a 3D neural culture platform derived from human neural progenitors, demonstrating that UBB+1 alone induces extracellular amyloid-β (Aβ) deposits and insoluble hyperphosphorylated tau aggregates. UBB+1 competes with ubiquitin for binding to the deubiquitinating enzyme UCHL1, leading to elevated levels of amyloid precursor protein (APP), secreted Aβ peptides, and Aβ build-up. Crucially, silencing UBB+1 expression impedes the emergence of AD hallmarks in this model system. Our findings highlight the significance of ubiquitin signalling as a variable contributing to AD pathology and present a nonclinical platform for testing potential therapeutics.
UR - http://www.scopus.com/inward/record.url?scp=85171895498&partnerID=8YFLogxK
U2 - 10.1038/s41467-023-41545-7
DO - 10.1038/s41467-023-41545-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37739965
AN - SCOPUS:85171895498
SN - 2041-1723
VL - 14
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5922
ER -